| Id: | acc2524 |
| Group: | 2sens |
| Protein: | JNK2 |
| Gene Symbol: | MAPK9 |
| Protein Id: | P45984 |
| Protein Name: | MK09_HUMAN |
| PTM: | phosphorylation |
| Site: | unclear |
| Site Sequence: | |
| Disease Category: | Cancer |
| Disease: | Colorectal Cancer |
| Disease Subtype: | |
| Disease Cellline: | HepG2 |
| Disease Info: | |
| Drug: | TRAIL + 5-fluorouracil (6-FU) |
| Drug Info: | "TRAIL - 5-Fluorouracil (5-FU) is a pyrimidine analog antimetabolite and antineoplastic agent that inhibits thymidylate synthase, thereby interfering with DNA synthesis and repair, and is used in the treatment of various cancers including colorectal, breast, and gastrointestinal malignancies." |
| Effect: | enhance |
| Effect Info: | Protein phosphorylation enhances the effectiveness of drug treatment. |
| Note: | drug comb |
| Score: | 5.0 |
| Pubmed(PMID): | 15837763 |
| Sentence Index: | 15837763_9-10 |
| Sentence: | "RESULTS: GSH depletion enhanced apoptosis induced by TRAIL/cisplatin (CDDP) or TRAIL/5-fluorouracil (5-FU) combinations in both human HT29 colon carcinoma and HepG2 hepatocarcinoma cells, whereas it enhanced cytotoxicity induced only by TRAIL/CDDP in human primary hepatocytes. Our results further suggested that GSH depletion enhanced SAPK/JNK phosphorylation upon TRAIL/5-FU exposure and likely reduced the detoxification mechanisms of CDDP in HT29 cells." |
Sequence & Structure:
MSDSKCDSQFYSVQVADSTFTVLKRYQQLKPIGSGAQGIVCAAFDTVLGINVAVKKLSRPFQNQTHAKRAYRELVLLKCVNHKNIISLLNVFTPQKTLEEFQDVYLVMELMDANLCQVIHMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTACTNFMMTPYVVTRYYRAPEVILGMGYKENVDIWSVGCIMGELVKGCVIFQGTDHIDQWNKVIEQLGTPSAEFMKKLQPTVRNYVENRPKYPGIKFEELFPDWIFPSESERDKIKTSQARDLLSKMLVIDPDKRISVDEALRHPYITVWYDPAEAEAPPPQIYDAQLEEREHAIEEWKELIYKEVMDWEERSKNGVVKDQPSDAAVSSNATPSQSSSINDISSMSTEQTLASDTDSSLDASTGPLEGCR
Select PDB:
| Target | Drug name | MOA | Phase | Status | Disease | Source |
|---|---|---|---|---|---|---|
| MAPK9 | BENTAMAPIMOD | c-Jun N-terminal kinase, JNK inhibitor | 2 | Completed | endometriosis | ClinicalTrials |
| MAPK9 | TANZISERTIB | c-Jun N-terminal kinase 2 inhibitor | 2 | Terminated | idiopathic pulmonary fibrosis | ClinicalTrials |
| MAPK9 | TANZISERTIB | c-Jun N-terminal kinase 2 inhibitor | 2 | Terminated | lupus erythematosus | ClinicalTrials |
| MAPK9 | CC-401 | c-Jun N-terminal kinase 2 inhibitor | 1 | Terminated | myeloid leukemia | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTAC| MAPK9-Tyr185 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | |
| HGSC | |
| ccRCC | |
| GBM | 0.707 |
| HNSC | |
| LUAD | |
| LUSC | |
| non_ccRCC | -0.707 |
| PDAC | |
| UCEC | |
PTM-Disease Association:
source: PTMDNo data.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
